Management of Atrial Fibrillation with Relative Basophilia

Understanding Relative Basophilia

Relative basophilia occurs when the absolute basophil count remains within normal range but the percentage appears elevated due to reduction in other white cell populations, most commonly neutropenia or lymphopenia, according to the American Heart Association, as reported in Stroke 1
In the context of recent fall and possible infection/inflammation, this likely represents a transient reactive change in white cell distribution, as noted by the Journal of the American Geriatrics Society 2

Elderly patients (≥75 years) with atrial fibrillation have approximately 23.5% of ischemic strokes attributable to AF, making anticoagulation critically important, as stated by the Journal of the American Geriatrics Society 2
The American College of Cardiology recommends that apixaban reduces stroke risk by 64-68% compared to aspirin or no treatment in atrial fibrillation patients, with a strength of evidence rated as high 3

The American College of Cardiology states that age per se is not a contraindication to anticoagulation in high-risk atrial fibrillation patients, as stroke prevention benefit exceeds bleeding risk in the vast majority of cases, with a level of evidence rated as A 4
The European Heart Rhythm Association emphasizes that a Markov decision model demonstrates patients would need to fall 295 times per year before the risk of subdural hemorrhage from falls outweighs the stroke prevention benefit of anticoagulation, with a strength of evidence rated as moderate 5
Elderly patients (≥75 years) have approximately twice the bleeding risk during anticoagulation compared to younger patients, but anticoagulation remains warranted when ischemic stroke risk exceeds bleeding risk, as reported in Stroke and Circulation 1, 4

The standard dose of apixaban is 5 mg twice daily, but should be reduced to 2.5 mg twice daily if ≥2 of the following criteria are met: age ≥80 years, weight ≤60 kg, or serum creatinine ≥1.5 mg/dL, as recommended by the FDA and reported in Circulation 4

The American College of Cardiology recommends targeting blood pressure <140/90 mmHg, ideally <130/80 mmHg, to reduce both ischemic stroke risk and intracranial hemorrhage risk during anticoagulation, with a strength of evidence rated as high 3
Poorly controlled hypertension is the most important modifiable risk factor for bleeding complications during anticoagulation, as reported in Stroke and Circulation 1, 4

The American Heart Association recommends reviewing complete blood count with differential to identify which cell line is reduced (causing the relative basophil elevation), as reported in Stroke 1
The European Heart Rhythm Association suggests monitoring for signs of bleeding, such as unusual bruising, prolonged bleeding, blood in urine or stool, severe headache, or dizziness, with a strength of evidence rated as moderate 5

The European Heart Rhythm Association emphasizes that age alone does not contraindicate anticoagulation, even after a fall, and that the stroke prevention benefit far outweighs subdural hemorrhage risk unless falls are occurring multiple times weekly, with a strength of evidence rated as moderate 5
The American College of Cardiology recommends not adding aspirin to apixaban, as it only increases bleeding without additional stroke benefit, with a level of evidence rated as A 3